Not yet recruiting NCT06300216
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Octreotide microspheres.
- Who it may be relevant to
- Registry conditions: Neuroendocrine Tumors. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.
Interventions
- Drug Octreotide microspheres
20mg/30mg Q4W
Primary outcome measures
- Treatment Emergent Adverse Events [Time frame: up to 46 months]
Eligibility criteria
Inclusion criteria
- Sign an informed consent form and voluntarily participate in this study;
- Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study;
- Age ≥ 18 years old;
- Treatment with octreotide microspheres.
Exclusion criteria
- Confirmed pregnant or lactating women;
- Participating in any research with intervention measures outside of routine clinical practice;
- Other situations unsuitable for inclusion in the study determined by the researcher.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Qilu hospital of Shandong University — Jinan
Identifiers
NCT: NCT06300216 · KYLL-202401-034-1